Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Japan NHI Lists Pfizer’s Celsentri, Janssen’s Intelence for HIV

This article was originally published in PharmAsia News

Executive Summary

TOKYO - Japan's Ministry of Health, Labor and Welfare Jan. 16 posted for emergency national health coverage two HIV drugs - Pfizer's Celsentri (maraviroc) 150mg tablet and Janssen's Intelence (etravirine) 100mg tablet

You may also be interested in...



Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains

TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has listed 11 new composites for national health insurance reimbursement coverage

Novartis Gains Four New Drugs Under Japan NHI Reimbursement; Astellas, Takeda, BMS, GSK Make Gains

TOKYO - At the recommendation of the Central Social Insurance Medical Council, known as Chuikyo in Japanese, the Ministry of Health, Labor and Welfare has listed 11 new composites for national health insurance reimbursement coverage

Japan To List Nine Composites For National Health Insurance Coverage

TOKYO - At its Dec. 3 plenary meeting, Chuikyo (the Central Social Insurance and Medical Council), the government-private body that sets Japan's medical and pharmaceutical policies, approved the listing of nine composites for 13 pharmaceutical products, including the relisting of Fujimoto's Thaled (thalidomide) for multiple myeloma

UsernamePublicRestriction

Register

AG002833

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel